SCNX to reverse split 1-for-25 to meet Nasdaq bid price

Scienture Holdings, Inc. (NASDAQ: SCNX) will execute a 1-for-25 reverse stock split of its common shares, a move expected to take effect before markets open on Monday, October 5, 2026. The company stated that this action is intended to help it maintain compliance with Nasdaq's minimum bid price requirement and to make additional shares available for future issuance.

As of September 30, 2026, Scienture has 41,064,146 shares of common stock issued and outstanding. Following the reverse split, the company expects this number to decrease to approximately 1,642,565 shares. The new CUSIP number for the common stock will be 80880X203. The par value per share and the total number of authorized shares will remain unchanged by the transaction.

At the effective time, every 25 shares of issued and outstanding common stock will be automatically converted into one share. Stockholders holding shares through brokerage accounts will see their holdings automatically adjusted to reflect the new ratio. The company stated that no fractional shares will be issued; instead, stockholders of record entitled to fractional shares will receive a cash payment in lieu of those fractions. Proportional adjustments will also be applied to the number of shares issuable upon the exercise or conversion of equity awards, convertible preferred stock, and warrants, as well as to the applicable exercise or conversion prices.

The adjustment applies equally across the shareholder base without changing any individual's proportional ownership stake in the company's equity, except where a fractional share entitlement occurs. Stockholders with shares in brokerage accounts are advised to direct questions regarding the adjustment to their brokers. All other stockholders may direct questions to the company's transfer agent, Continental Stock Transfer & Trust Company.

Scienture Holdings describes itself as a holding company for existing and planned pharmaceutical operating companies focused on developing, commercializing, and distributing novel specialty products. Through its wholly owned subsidiary, Scienture, LLC, the company aims to provide enhanced value to patients, physicians, and caregivers by addressing unmet market needs with branded specialty pharmaceuticals. The company's assets in development span various therapeutic areas and indications.

The press release includes cautionary statements regarding forward-looking statements under federal securities laws. These statements reflect current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Risks cited include the company's ability to raise funding, maintain its Nasdaq listing, and continue as a going concern, as well as legal proceedings and intellectual property claims. Scienture undertakes no obligation to update forward-looking statements except as required by law.